3-(2,6-dichloro-phenyl)-5-methyl-isoxazole | 31007-73-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2,6-dichloro-phenyl)-5-methyl-isoxazole
• 英文别名: 3-(2,6-Dichlorophenyl)-5-methylisoxazole；3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole
• CAS: 31007-73-5
• 化学式: C₁₀H₇Cl₂NO
• 分子量: 228.078
• InChiKey: HQIMFAPFKHPNLG-UHFFFAOYSA-N

物化性质

• 沸点：
  308.1±37.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,6-二氯苯甲腈 N-氧化物 在 甲酸 、 双氧水 作用下， 以 乙醚 为溶剂， 反应 32.0h， 生成 3-(2,6-dichloro-phenyl)-5-methyl-isoxazole
  参考文献：
  名称：

  Bianchetti, Giuseppe; Pocar, Donato; Torricelli, Clara, Gazzetta Chimica Italiana, 1981, vol. 111, # 7/8, p. 315 - 324

  摘要：

  DOI：

文献信息

• Reaction of allenylmagnesium and allenylindium bromides with nitrile oxides: synthesis of novel 5-butynyl- and 5-methylisoxazoles
  作者：H.M. Sampath Kumar、Parvinder Pal Singh、Syed Shafi、Pitta Bhaskar Reddy、Kankala Shravankumar、Doma Mahender Reddy

  DOI：10.1016/j.tetlet.2006.11.140

  日期：2007.1

  obtained in high yields through a domino addition, C–O heterocyclization involving allenylmagnesium bromide and benzonitrile oxide in dry THF, in which the corresponding 5-methylisoxazoles were isolated in trace amounts. However, when the reactions were attempted in aqueous media using allenylindium bromide, 5-methylisoxazoles were formed as the sole products in high yields.

  通过将多烯基溴化镁和苯甲腈氧化物在干燥的THF中进行多米诺骨牌加成，C–O杂环化，可以高收率地获得5-丁炔基异恶唑，其中分离出痕量的相应的5-甲基异恶唑。然而，当尝试在含水介质中使用烯丙基溴化铟进行反应时，以高收率形成了5-甲基异恶唑作为唯一产物。
• Studies in isoxazole chemistry. IV. Isoxazoles via isoxazolines
  作者：R. G. Mlcetich

  DOI：10.1139/v70-629

  日期：1970.12.1

  4- or 5-Chloro- or cyanoisoxazoles, 5-chloromethylisoxazoles, and 5-methylisoxazoles were made by the 1,3-dipolar cycloaddition of nitrile oxides to α-halogeno- or α-alkoxyolefins. In the case of cis- and trans-1,2-dichloroethylene, (5a and b) the intermediate cis- and trans-4,5-dichloroisoxalines (6a and b) were isolated. Both 6a and b were dehydrochlorinated with base to give the 4-chloroisoxazole (7a) exclusively. The cis-isomer 6a reacted faster than the trans-somer 6b. The reactions were found to be specific in every reaction since only one isomer was isolated. The structures of the products were established from n.m.r. spectral analysis.

  4-氯或5-氯或氰基异噁唑，5-氯甲基异噁唑和5-甲基异噁唑通过腈氧化物与α-卤代烯或α-烷氧基烯的1,3-偶极环加成制备。对于顺式和反式-1,2-二氯乙烯，中间体顺式和反式-4,5-二氯异恶二烯（6a和b）被分离。6a和b都被碱脱氯化以独占地得到4-氯异噁唑（7a）。顺式异构体6a的反应速度比反式异构体6b快。在每个反应中都发现反应是特异的，因为只分离出一种异构体。产品的结构是通过核磁共振谱分析确定的。
• Cephalosporins, process for their preparation and pharmaceutical compositions containing them
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0229369A2

  公开（公告）日：1987-07-22

  A compound of the general formula: wherein R° is hydrogen, a nitrogen-containing heterocyclic group, an acyl group or an amino-protective group; Z is S, S→O,O or CH2; R4 is hydrogen, a methoxy or formamido; R" is hydrogen, methyl, hydroxyl or halogen; and A is an optionally substituted condensed cyclic cationic group consisting of the same or different two 5- or 6-membered nitrogen-containing heterocyclic rings sharing a C-N bond with each other, , or a salt or ester thereof. , and a process for preparing the same and a pharmaceutical composition thereof are disclosed.

  本发明公开了一种通式如下的化合物：其中 R°是氢、含氮杂环基团、酰基或氨基保护基团；Z 是 S、S→O、O 或 CH2；R4 是氢、甲氧基或甲酰胺基；R "是氢、甲基、羟基或卤素；A 是由相同或不同的两个 5 元或 6 元含氮杂环彼此共用一个 C-N 键组成的任选取代的缩合环阳离子基团、Ⅳ或其盐或酯、Ⅳ及其制备方法和药物组合物。
• Inhibitors of Hepatitis C virus NS3 serine protease
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2314598A1

  公开（公告）日：2011-04-27

  The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and_methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.

  本发明涉及用于抑制蛋白酶，特别是丝氨酸蛋白酶，更特别是HCV NS3蛋白酶的化合物、方法和药物组合物。这些化合物以及利用它们的组合物和方法可单独或联合用于抑制病毒，特别是 HCV 病毒。
• Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2409985A2

  公开（公告）日：2012-01-25

  The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.

  本发明涉及用于抑制蛋白酶，特别是丝氨酸蛋白酶，尤其是 HCV NS3 蛋白酶的化合物、方法和药物组合物。这些化合物以及利用它们的组合物和方法可单独或联合用于抑制病毒，特别是 HCV 病毒。